Oramed Pharmaceuticals Inc. (OTC BB: ORMP), a commercial drug development company, is applying proprietary expertise in integrative pharmacology to potentially discover new uses for drug candidates. Currently, the company is committing their efforts to developing certain compounds for new uses. Compounds in Ore’s development pipeline include: romazarit (for metabolic disorders), tiapamil (for treatment of diseases of the central nervous system), and GL1001 (for inflammatory bowel disease). For further information, visit the Company’s web site at www.oramed.com.
- 18 years ago
QualityStocks
Oramed Pharmaceuticals Inc. (OTC BB: ORMP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Why TruGolf Holdings Inc. (NASDAQ: TRUG) Is ‘One to Watch’
TruGolf (NASDAQ: TRUG) is pursuing a strategic expansion into blockchain-based financial infrastructure through its pending…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Brings Interactive Experiences to Major Sports and Entertainment Audiences
Versus Systems (NASDAQ: VS) uses gamification and audience engagement technology to help brands, sports teams,…
-
QualityStocksNewsBreaks – BOXABL Inc. (NASDAQ: BXBL) Builds Momentum with Potential 1,500-Home Pipeline
BOXABL (NASDAQ: BXBL) has signed a multiyear purchase agreement with LC Vegas Acquisitions, LLC for…